MeiraGTx/$MGTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About MeiraGTx
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Ticker
$MGTX
Sector
Primary listing
Employees
386
Headquarters
Website
MeiraGTx Metrics
BasicAdvanced
$654M
-
-$2.03
1.30
-
Price and volume
Market cap
$654M
Beta
1.3
52-week high
$8.98
52-week low
$4.55
Average daily volume
374K
Financial strength
Current ratio
0.881
Quick ratio
0.729
Long term debt to equity
2,629.122
Total debt to equity
2,718.547
Interest coverage (TTM)
-12.29%
Profitability
EBITDA (TTM)
-145.318
Gross margin (TTM)
26.56%
Net profit margin (TTM)
-415.39%
Operating margin (TTM)
-416.49%
Revenue per employee (TTM)
$100,000
Management effectiveness
Return on assets (TTM)
-42.42%
Return on equity (TTM)
-379.53%
Valuation
Price to revenue (TTM)
16.643
Price to book
220.96
Price to tangible book (TTM)
294.88
Price to free cash flow (TTM)
-4.71
Free cash flow yield (TTM)
-21.23%
Free cash flow per share (TTM)
-1.726
Growth
Revenue change (TTM)
366.84%
Earnings per share change (TTM)
36.36%
3-year revenue growth (CAGR)
-5.11%
3-year earnings per share growth (CAGR)
-3.69%
What the Analysts think about MeiraGTx
Analyst ratings (Buy, Hold, Sell) for MeiraGTx stock.
Bulls say / Bears say
MeiraGTx formed a strategic partnership with Hologen AI, gaining $200 million upfront and commitments for up to $230 million more to speed up its Phase 3 AAV-GAD program for Parkinson’s disease.
The FDA granted Regenerative Medicine Advanced Therapy (RMAT) designation to MeiraGTx’s AAV-GAD program for Parkinson’s disease in May 2025, offering an accelerated review process and signaling strong clinical benefit.
RBC Capital Markets increased its price target for MGTX to $13.00 and kept an Outperform rating, reflecting confidence in MeiraGTx’s partnerships and late-stage pipeline progress.
MeiraGTx reported a first-quarter loss per share of $0.51, missing the Zacks consensus estimate of a $0.38 loss and highlighting ongoing profitability issues.
Cash and cash equivalents at MeiraGTx fell to $32.2 million as of June 30, 2025, fueling concerns about the company's cash runway given its high usage rate.
The company faces a $75 million debt maturity in August 2026, creating refinancing risk amid ongoing R&D expenses.
Data summarised monthly by Lightyear AI. Last updated on 2 Oct 2025.
MeiraGTx Financial Performance
Revenues and expenses
MeiraGTx Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for MeiraGTx stock?
MeiraGTx (MGTX) has a market cap of $654M as of October 18, 2025.
What is the P/E ratio for MeiraGTx stock?
The price to earnings (P/E) ratio for MeiraGTx (MGTX) stock is 0 as of October 18, 2025.
Does MeiraGTx stock pay dividends?
No, MeiraGTx (MGTX) stock does not pay dividends to its shareholders as of October 18, 2025.
When is the next MeiraGTx dividend payment date?
MeiraGTx (MGTX) stock does not pay dividends to its shareholders.
What is the beta indicator for MeiraGTx?
MeiraGTx (MGTX) has a beta rating of 1.3. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.